Subject to approval, Guido Rasi, the current head of the Italian Medicines Agency, has been nominated to run the European Medicines Agency after a search process that has drawn fire from critics and the European Parliament.
It was controversy over Mr. Lonngren’s departure and his subsequent new position within the pharmaceutical industry that helped cast a shadow over the search process. Since Mr. Lonngren left the EMA, criticism has been mounting about him taking up a job with a pharma consultancy NDA directly after leaving the agency.
Our own head of the Irish Medicines Board Mr. Pat O’Mahony, had been considered a front-runner for Thomas Lonngren’s job, but he fell out of favor because he personally approved Lonngren’s consulting job without even mentioning the potential for conflicts.
When it emerged that Mr. O’Mahony had personally approved Lönngren’s move to NDA, and had raised no concerns about conflict of interest, doubts about his own judgement became an issue. Link
He was interviewed here in the “Irish pharmacist” which by the looks of it is just an advertising platform for pharmaceutical companies including lundbeck and escitalopram, which by the way, lundbeck got into big trouble for in the UK for false advertising, when lexapro/cipralex was found to be identical to cipramil, but hey, that’s another story! BMJ.
There is also an advertisment in here for chantix/champix, the smoking cessation drug, which has the worst drug safety record with more reported serious injuries than any other prescription drug even before Pat O’Mahony did this interview in 2009, but strangely no mention of it, but I doubt if pfizer would acknowledge the serious side effects… No that’s Pat O’Mahonys job!
Then again, concerns have arisen before with conflicts of interest and the IMB, and the fact that Pat O’Mahony worked as a technical manager in the veterinary pharmaceutical industry in Ireland and the UK. Link
It seems that any investigation into citalopram is up to Pat O’Mahony, and the fact that I have informed the IMB of all the information, concerns over the licencing of cipramil, lundbeck admitting suicide/homicide, hidden and false advertising, coroner’s concerns with citalopram, an expert medical report ect, I honestly don’t know what the problem is, unless of course “conflict of interest” also means that Mr. O’Mahony doesn’t want to upset the pharmaceutical companies who make these antidepressants because you can be sure that lundbeck’s cipramil is not the only problem drug in this class!
- EMA investigates conflicts of interest involving officials and pharma (fiercebiotech.com)